Shinpoong enters into exclusive agreement with HRA Pharma over Ulipristal, uterine fibroids drug
Published: 2010-12-06 06:57:00
Updated: 2010-12-06 06:57:00
Shinpoong Pharmaceutical said on December 2 that it has signed an exclusive licensing agreement with France based HRA Pharma to develop and commercialize ulipristal acetate in Korea for benign gynecological disorders, with a lead indication for the treatment of symptomatic uterine fibroids.
Ul...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
